The Scripps Research Institute

The J. David Gladstone Institutes, a Testamentary Trust Established Under the Will of J. David Gladstone

University of California

Irm LLC

University of Washington

The J. David Gladstone Institutes

The Salk Institute for Biological Studies

The J. David Gladstone Institute, a Testamentary Trust Established Under the Will of J. David Gladstone

The J. David Gladstone Institutes, a Teatamentary Trust Established Under the Will of J. David. Gladstone

The J. David Gladstone Ins., a Testamentary Trust Established Under the Will of J. David Gladstone

Sheng Ding

Saiyong Zhu

Peter G Schultz

Tongxiang Lin

Wenlin Li

Yue Xu

Hongyan Zhou

Nathanael Schiander Gray

Caroline Desponts

Yan Shi

Shuibing C Chen

Janghwan Kim

Jem A Efe

Simon Hilcove

Fred Harrison Gage

Qiang Ding

Thomas A Reh

Tomoko Kuwabara

Holger Willenbring

Milad Rezvani

Jack Harbell

Masaki Warashina

Kyung Hoon Min

Paul Nakamura

Ke Li

Kang Zhang

Xu Wu

Matthias Hebrok

Nan Cao

Jiayu Liao

Holger Andreas Russ

Tao Xu

Changsheng Lin

Tom Wu

Peng Liu

Mingliang Zhang

Haixia Wang

Yuanxiang Zhao

The present invention relates compounds for stabilizing cells and methods of their use.

Methods of enhancing cell survival of stem cells

The slow kinetics and low efficiency of reprogramming methods to generate human induced pluripotent stem cells (iPSCs) impose major limitations on their utility in biomedical applications. Here we describe a chemical approach that dramatically improves (>200 fold) the efficiency of iPSC generation from human fibroblasts, within seven days of treatment. This will provide a basis for developing safer, more efficient, non-viral methods for reprogramming human somatic cells.

Induction of pluripotent cells

The present Application is related to methods and compositions for reprogramming adult somatic cells into induced pluripotent stem cells by targeting and remodeling endogenous gene loci without relying on ectopic expression of transcription factors.

Generation of induced pluripotent cells by CRISPR activation

Compositions and methods are described herein for chemically inducing cells to change their differentiation state and become neuronal cells.

Chemical reprogramming to generate neuronal cells

The present invention provides for the generation and maintenance of pluripotent cells by culturing the cells in the presence of an ALK5 inhibitor.

Generation and maintenance of stem cells

Compositions and methods of producing mammalian cell populations that include a high proportion of pancreatic beta cells are described herein. Such cell populations are useful for treatment of diabetes. Also provided are materials and methods for the direct differentiation of stem cells, such as embryonic stem cells, into functional pancreatic beta cells. The disclosure provides the benefit of direct differentiation, which results in the production of functional pancreatic beta cells efficiently and at low cost.

Methods and compositions for producing pancreatic beta cells

Provided herein are methods for treating an individual for a disease (e.g., an autoimmune disease or a cancer) using an active agent which affects metabolism of &#x3b1;-ketoglutarate (&#x3b1;-KG) and/or 2-hydroxyglutarate (2-HG) in differentiating T cells. In some embodiments, a Got1 inhibitor is used to generate a population of T cells enriched in peripheral regulatory T (iTreg) cells, which population enriched in iTreg cells may find use in treating an autoimmune disease. In some embodiments, a TCA cycle-associated metabolite, or a derivative thereof, is used to generate a population of T cells in enriched in IL-17- and IL-17F-producing CD4 T (T17) cells, which population enriched in T17 cells may find use in treating a cancer.

Methods of treating disease by metabolic control of T-cell differentiation

The slow kinetics and low efficiency of reprogramming methods to generate human induced pluripotent stem cells (iPSCs) impose major limitations on their utility in biomedical applications. Here we describe a chemical approach that dramatically improves (&#x3e;200 fold) the efficiency of iPSC generation from human fibroblasts, within seven days of treatment. This will provide a basis for developing safer, more efficient, non-viral methods for reprogramming human somatic cells.

The present invention generally provides methods and compositions for transdifferentiation of an animal cell from a first non-pluripotent cell fate to a second non-pluripotent cell fate. Also provided are methods and compositions for the transdifferentiation of an animal cell from a non-pluripotent mesodermal, endodermal, or ectodermal cell fate to a different non-pluripotent mesodermal, endodermal, or ectodermal cell fate.

Reprogramming of cells to a new fate

Methods for decreasing rod gene expression in a retina, methods for decreasing the protein products expressed by rod genes in a retina, methods for treating a disease or condition treatable by decreasing rod gene expression or their protein products in a retina, and methods for treating a retinal disease in a subject.

Methods for treatment of retinal disease by photoreceptor gene expression modulation

The present invention provides for methods, compositions, and kits for producing an induced pluripotent stem cell from a non-pluripotent mammalian cell using a 3'-phosphoinositide-dependent kinase-1 (PDK1) activator or a compound that promotes glycolytic metabolism as well as other small molecules.

Reprogramming cells

Small molecule cellular reprogramming to generate neuronal cells

Growing community of inventors

Orinda, CA, United States of America

Sheng Ding